Gilead Sciences (GILD) Construction in Progress (2010 - 2025)
Gilead Sciences (GILD) reported Construction in Progress of $745.0 million for Q4 2025, up 48.7% on a YoY basis from $501.0 million in Q4 2024, and up 48.7% quarter-over-quarter from $501.0 million in Q4 2024.
Gilead Sciences (GILD) Construction in Progress (2010 - 2025) Analysis & Trends
Gilead Sciences has reported Construction in Progress for 16 years, with the latest figure at $745.0 million in Q4 2025.
- For the quarter ending Q4 2025, Construction in Progress rose 48.7% year-over-year to $745.0 million; the trailing twelve-month figure through Dec 2025 stood at $745.0 million (up 48.7% YoY), and the FY2025 full-year result was $745.0 million, up 48.7% from the prior year.
- Construction in Progress for Q4 2025 stood at $745.0 million, up from $501.0 million in the prior quarter.
- The five-year high for Construction in Progress was $1.1 billion in Q4 2021, with the low at $501.0 million in Q4 2024.
- Historically, Construction in Progress has averaged $736.6 million across 5 years, with a median of $719.0 million in 2022.
- Annual changes were most pronounced in 2022 — Construction in Progress tumbled 31.98% — and 2025, when it jumped 48.7%.
- Gilead Sciences' Construction in Progress stood at $1.1 billion in 2021, then plunged by 31.98% to $719.0 million in 2022, then retreated by 8.07% to $661.0 million in 2023, then retreated by 24.21% to $501.0 million in 2024, then jumped by 48.7% to $745.0 million in 2025.
- The last three Construction in Progress figures came in at $745.0 million (Q4 2025), $501.0 million (Q4 2024), and $661.0 million (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | - |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | - |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | - |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | - |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 1.54 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 745.00 Mn |
| Dec 31, 2024 | 501.00 Mn |
| Dec 31, 2023 | 661.00 Mn |
| Dec 31, 2022 | 719.00 Mn |
| Dec 31, 2021 | 1.06 Bn |
| Dec 31, 2020 | 856.00 Mn |
| Dec 31, 2019 | 723.00 Mn |
| Dec 31, 2018 | 1.19 Bn |
| Dec 31, 2017 | 690.00 Mn |
| Dec 31, 2016 | 641.00 Mn |
| Dec 31, 2015 | 554.00 Mn |
| Dec 31, 2014 | 411.00 Mn |
| Dec 31, 2013 | 129.00 Mn |
| Dec 31, 2012 | 216.43 Mn |
| Dec 31, 2011 | 60.75 Mn |
| Dec 31, 2010 | 82.33 Mn |